Fate Therapeutics (FATE)
NASDAQ:FATE

Fate Therapeutics Stock Price & Analysis

931 Followers

FATE Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$17.10 - $66.56
Previous Close$19.84
Volume1.42M
Average Volume (3M)1.31M
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$505.14M
Total Debt (Recent Filing)$110.92M
Price to Earnings (P/E)-6.5
Beta1.70
Next EarningsFeb 27, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
EPS (TTM)-3.05
Shares Outstanding97,170,443
R-Squared0.19
Standard Deviation0.19
10 Day Avg. Volume915,049
30 Day Avg. Volume1,306,760
Price to Book (P/B)3.61
Price to Sales (P/S)27.93
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-6.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target Upside248.22% Upside
Rating ConsensusStrong Buy
Alpha0.03
Number of Analyst Covering10


Financials


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

FATE FAQ

What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was $17.10 and its highest was $66.56 in the past 12 months.
    What is Fate Therapeutics’s market cap?
    Currently, no data Available
    When is Fate Therapeutics’s upcoming earnings report date?
    Fate Therapeutics’s upcoming earnings report date is Feb 27, 2023 which is in 88 days.
      How were Fate Therapeutics’s earnings last quarter?
      Fate Therapeutics released its earnings results on Nov 03, 2022. The company reported -$0.86 earnings per share for the quarter, beating the consensus estimate of -$0.895 by $0.035.
        Is Fate Therapeutics overvalued?
        According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Fate Therapeutics pay dividends?
          Fate Therapeutics does not currently pay dividends.
          What is Fate Therapeutics’s EPS estimate?
          Fate Therapeutics’s EPS estimate is -$0.88.
            How many shares outstanding does Fate Therapeutics have?
            Fate Therapeutics has 97,170,440 shares outstanding.
              What happened to Fate Therapeutics’s price movement after its last earnings report?
              Fate Therapeutics reported an EPS of -$0.86 in its last earnings report, beating expectations of -$0.895. Following the earnings report the stock price went up 2.005%.
                Which hedge fund is a major shareholder of Fate Therapeutics?
                Among the largest hedge funds holding Fate Therapeutics’s share is ARK Investment Management LLC. It holds Fate Therapeutics’s shares valued at 261M.

                  ---

                  Fate Therapeutics Stock Smart Score

                  9
                  Outperform
                  1
                  2
                  3
                  4
                  5
                  6
                  7
                  8
                  9
                  10

                  Technicals

                  SMA
                  Negative
                  20 days / 200 days
                  Momentum
                  -61.67%
                  12-Months-Change

                  Fundamentals

                  Return on Equity
                  -47.10%
                  Trailing 12-Months
                  Asset Growth
                  -23.89%
                  Trailing 12-Months
                  The Fate Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Fate Therapeutics

                  Fate Therapeutics, Inc. operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system. Its products include ProHema, ProTmune, Adaptive NK, iPSC-derived NK, Programmed CD34 and T cell therapy. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

                  ---

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Akero Therapeutics
                  ProKidney
                  ImmunityBio
                  Revolution Medicines
                  Krystal Biotech

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis